Dosing in Heavy-weight/Obese Patients with the LMWH, Tinzaparin: A Pharmacodynamic Study

Summary

This pharmacodynamic study examined weight-based dosing of the low molecular weight heparin (LMWH), tinzaparin, in heavyweight/obese subjects. Single doses (175 and 75 IU/kg) were administered subcutaneously (SC) to 37 healthy heavy-weight subjects (101-165 kg; 26-61 kg/m²). AUA and Amax values of anti-Xa and anti-IIa activities were consistent over these body weight and body mass index (BMI) ranges, indicating that tinzaparin pharmacodynamics are not influenced by body weight or BMI. The range of AUA and Amax values in the study population overlapped that of historical control normal-weight subjects (<100 kg), indicating that weightadjusted tinzaparin dosing yields a predictable response regardless of body weight or BMI. Tinzaparin was well tolerated, although injection site bruising was commonly reported. SC tinzaparin dosing in heavy or obese patients is appropriate based on body weight alone; the dose need not be capped at a maximal absolute dose.

Keywords

Low molecular weight heparin - tinzaparin - obesity - weight-based dosing - Innohep

• References

• 1 Hirsch J, Warkentin TE, Shanghnessy SG, Anand SS, Halperin JI, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight heparin. Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. CHEST 2000; 119: 64S-94S.
• 2 Hull RD, Raskob GE, Pineo G, Green D, Trowbridge AA, Elliott CG, Lerner RG, Hall J, Sparling T, Brettell HR, Norton J, Carter CJ, George R, Merli G, Ward J, Mayo W, Rosenbloom D, Brant R. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326: 975-82.
• 3 Hull RD, Raskob G, Pineo G, Rosenbloom D, Evans W, Mallory T, Anquist K, Smith F, Hughes G, Green D, Elliott CG, Panju A, Brant R. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med 1993; 329: 1370-6.
• 4 Mätzsch T, Bergqvist D, Hedner U, Ostergaard P. Effects of an enzymatically depolymerized heparin as compared with conventional heparin in healthy volunteers. Thromb Haemost 1987; 57: 97-101.
• 5 Barrett JS, Hainer JW, Kornhauser DM, Gaskill JL, Hua TA, Sprogel P, Johansen K, van Lier JJ, Knebel W, Pieniaszek Jr HJ. Anticoagulant pharmacodynamics of tinzaparin following 175 IU/kg subcutaneous administration to healthy volunteers. Thromb Res 2001; 101: 243-54.
• 6 Kuczmarski RJ, Carroll MD, Flegal KM, Troiano RP. Varying body mass index cutoff points to describe overweight prevalence among U.S. adults: NHANES III (1988 to 1994). Obes Res 1997; 05: 542-8.
• 7 Pedersen PC, Ostergaard PB, Hedner U, Bergqvist D, Matzsch T. Pharmacokinetics of a low molecular weight heparin, Logiparin, after intravenous and subcutaneous administration to healthy volunteers. Thromb Res 1991; 61: 477-87.
• 8 U.S. Innohep® Package Insert, Bristol-Myers Squibb Company. May 2001
• 9 Wilson SJA, Wilbur K, Burton E, Anderson DR. Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular-weight heparin for the treatment of venous thromboembolism. Haemostasis 2001; 31: 42-8.
• 10 Sanderink GJ, Liboux AL, Jariwala N, Harding N, Ozoux M-L, Shukla U, Montay G, Boutouyrie B, Miro A. Enoxaparin pharmacokinetics and pharmacodynamics in obese subjects [abstract]. J Am Coll Cardiol. 2001 37. (Suppl A) 229A. (#1076-172).
• 11 Duplaga BA, Rivers CW, Nutescu E. Dosing and monitoring of low-molecular-weight heparins in special populations. Pharmacotherapy 2001; 21: 218-34.
• 12 Tinzaparin sodium NDA, DuPont Pharmaceuticals Company. June 1999
• 13 Fareed J, Jeske W, Hoppensteadt D, Clarizio R, Walenga JM. Low-molecular-weight heparins: Pharmacologic profile and product differentiation. Am J Cardiol 1998; 82: 3L-10L.